Results

1–10 of 262 results for Anti-VEGF

Rates of Post Intravitreal Anti-VEGF Injection Endophthalmitis: Management Strategies and Visual Acuity Outcomes From the AAO IRIS Registry
Alia K Durrani, MD
Annual Meeting Talks
2023
Impact of Initial Monthly Doses of Aflibercept on Visual Outcomes in Eyes With Diabetic Macular Edema in Routine Clinical Practice in the US
Ferhina S Ali, MD, MPH
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023
Aflibercept 8 mg for Diabetic Macular Edema: 2-Year Results of the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Annual Meeting Talks
2023
Interim Results of the Phase 1-2 PRISM Trial Evaluating 4D-150 a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration
Christine Kay, MD
Annual Meeting Talks
2023
Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results
Min Sagong, MD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023
Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Expert Panel: Socioeconomics
Linda A. Lam, MD, MBA, FASRS
Ella H Leung, MD
Mohsin H. Ali, MD
Hasenin Al-khersan, MD
Miguel A. Busquets, MD, FACS
Annual Meeting Talks
2024
Assessment on Pre-to-Post Switching Efficacy and Safety of SB15 (Proposed Aflibercept Biosimilar): Post Hoc Analysis of a Phase 3 Clinical Trial
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2024